drugset / Trial / NCT01404598

Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male

NCT01404598

Phase 1 Completed 24 enrolled NicOx
RandomizedParallel-groupOpen-labelBasic science

Summary

This study will be performed in 2 parts conducted in parallel: Part 1 (conducted on 16 healthy subjects): Administration of naproxcinod 750 mg or naproxen 500 mg twice a day (bid) during 7 days The main aim of this study part will be to assess the pharmacokinetic profile (i.e. the absorption, the distribution, the metabolism and the elimination of the drug after its administration) of nitrates (metabolite of naproxcinod) present in plasma, saliva and urine after oral administration of naproxcinod 750 mg bid for 7 days or naproxen 500 mg bid for 7 days as a reference. Part 2 (conducted on 8 healthy subjects): Administration of a single dose of naproxcinod 3000 mg. The main aim of this study part will be to assess the pharmacokinetic profile (i.e. the absorption, the distribution, the metabolism and the elimination of the drug after its administration) of Gamma-Hydroxybutyric Acid (GHB), a compound resulting from the transformation of the naproxcinod, after oral administration of a single supratherapeutic dose of 3000 mg.

Timeline

Start
2010-01
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject naproxcinod Other / unclassified 750 mg Oral
Subject naproxcinod Other / unclassified 3000 mg Oral
Comparator Naproxen Small molecule 500 mg Oral

Indications

No indication recorded.